Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 9/20 | 0.38 |
| ▸ | KDR | P35968 | 8/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22749223 | 0.84 | CNR2 (0.48) | CNR2CYP1A2CYP2C19FLT1KDR | |
| SCHEMBL22749207 | 0.83 | CNR2 (0.47) | CNR2CYP1A2CYP2C19FLT1KDR | |
| SCHEMBL19893070 | 0.79 | KDM4E (0.33) | CNR2KDM4EALDH1A1GAAMAPT | |
| SCHEMBL30926216 | 0.75 | ALDH1A1 (0.37) | CNR2KDM4EALDH1A1GAAMAPT | |
| SCHEMBL30908549 | 0.74 | CNR2 (0.59) | CNR2CYP1A2CYP2C19FLT1KDR | |
| SCHEMBL1881753 | 0.74 | CNR2 (0.55) | CNR2CYP1A2CYP2C19FLT1KDR | |
| SCHEMBL27409311 | 0.72 | CNR2 (0.56) | CNR2CYP1A2CYP2C19FLT1KDR | |
| SCHEMBL19893122 | 0.71 | CNR2 (0.47) | CNR2KDM4EALDH1A1GAAMAPT | |
| SCHEMBL31719625 | 0.70 | CNR2 (0.47) | CNR2CYP1A2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL2215634 | 0.70 | CNR2 (0.47) | CNR2CYP1A2CYP2C19KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3287441-B1 | ACYLATED 4-AMINOPIPERIDINES AS INHIBITORS OF SERINE PALMITOYLTRANSFERASE | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-10189785-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-21 | — | — | US | disclosed |
| EP-3287441-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189785-B2 | Heterocyclic compound | SPTLC1, SPTLC2, NPC1 | CNR2 1791/4885CYP1A2 3194/4885CYP2C19 4309/4885 |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | SPTLC1, SPTLC2, NPC1 | CNR2 1791/4885CYP1A2 3194/4885CYP2C19 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.